Lipodystrophy and insulin resistance in combination antiretroviral treated HIV-1-infected patients: Implication of resistin

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 1, 2011, Pages 16-23

  Escoté, Xavier ^a,b   Miranda, Merce ^a,b   Veloso, Sergi ^a   Domingo, Pere ^c   Alonso Villaverde, Carlos ^d   Peraire, Joaquim ^a   Viladés, Consuelo ^a   Alba, Verónica ^a   Olona, Montserrat ^a   Castro, Antoni ^d   López Dupla, Miguel ^a   Sirvent, Joan Josep ^a   Vicente, Vicente ^a   Vendrell, Joan ^a,b   Richart, Cristóbal ^a   Vidal, Francesc ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

combination antiretroviral therapy; HIV; insulin resistance; lipodystrophy; resistin

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RESISTIN; RITONAVIR; SAQUINAVIR; TENOFOVIR;

ADULT; ALLELE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSULIN RESISTANCE; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTHROPOMETRY; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RESISTIN; STATISTICS, NONPARAMETRIC;

EID: 79954997498     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318213312c     Document Type: Article

References (42)

1. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312. (Pubitemid 32151228)
2. Satoh H, Nguyen MT, Miles PD, et al. Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats. J Clin Invest. 2004;114:224-231. (Pubitemid 39071627)
3. Way JM, Gorgun CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator- activated receptor agonists. J Biol Chem. 2001;276:25651-25653.
4. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab. 2003;88:5452-5455. (Pubitemid 37452753)
5. Youn BS, Yu KY, Park HJ, et al. Plasma resistin concentrations measured by enzyme- linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2004;89:150-156. (Pubitemid 38183874)
6. Silha JV, Krsek M, Skrha JV, et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003;149:331-335. (Pubitemid 37304704)
7. Lee JH, Chan JL, Yiannakouris N, et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab. 2003;88:4848-4856. (Pubitemid 37357535)
8. Heilbronn LK, Rood J, Janderova L, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab. 2004;89:1844-1848. (Pubitemid 38507943)
9. Vozarova de Court, Degawa-Yamauchi M, Considine RV, et al. High serum Resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes. 2004;53:1279-1284. (Pubitemid 38569014)
10. Kamin D, Hadigan C, Lehrke M, et al. Resistin levels in human immunodeficiency virus-infected patients with lipoatrophy decrease in response to rosiglitazone. J Clin Endocrinol Metab. 2005;90:3423-3426. (Pubitemid 41014307)
11. Barb D, Wadhwa SG, Kratzsch J, et al. Circulating resistin levels are not associated with fat redistribution, insulin resistance, or metabolic profile in patients with the highly active antiretroviral therapy-induced metabolic syndrome. J Clin Endocrinol Metab. 2005;90:5324-5328. (Pubitemid 41262295)
12. Spagnuolo MI, Bruzzese E, Vallone GF, et al. Is resistin a link between highly active antiretroviral therapy and fat redistribution in HIV-infected children? J Endocrinol Invest. 2008;31:592-596.
13. Resino S, Micheloud D, Lorente R, et al. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy. HIV Med. 2011;12:54-60.
14. Osawa H, Tabara Y, Kawamoto R, et al. Plasma resistin, associated with single nucleotide polymorphism -420 is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C reactive protein in the Japanese general population. Diabetes Care. 2007;30:1501-1506. (Pubitemid 46871161)
15. Li M, Fisette A, Zhao XY, et al. Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents. Int J Obes (Lond). 2009;33:424-439.
16. Manduteanu I, Dragomir I, Calin M, et al. Resistin up-regulates fractalkine expression in human endothelial cells: Lack of additive effect with TNF-α. Biochem Biophys Res Commun. 2009;381:96-101.
17. Tang NP, Wang LS, Yang L, et al. A polymorphism in the Resistin gene promoter and the risk of coronary artery disease in a Chinese population. Clin Endocrinol. 2008;68:82-87. (Pubitemid 350243486)
18. Ranade K, Geese WJ, Noor M, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008;22:1561-1568.
19. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidae-mia and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099. (Pubitemid 29278477)
20. Christeff N, Melchior JC, de Truchis P, et al. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS. 1999;13:2251-2260. (Pubitemid 29531444)
21. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139. (Pubitemid 32150958)
22. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National health and Nutrition Examination. JAMA. 2002;287:356-359. (Pubitemid 34251969)
23. Mattews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419. (Pubitemid 15018832)
24. Saumoy M, López-Dupla M, Veloso S, et al. A study on the IL-6 system in HIV-1-infected patients. AIDS. 2008;22:893-896.
25. Auguet T, Vidal F, López-Dupla M, et al. A study on the TNF-a system in Caucasian Spanish patients with alcoholic liver disease. Drug Alcohol Depend. 2008;92:91-99. (Pubitemid 350218198)
26. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-735.
27. Maher B, Alfirevic A, Vilar FJ, et al. TNF-a promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS. 2002; 16:2013-2018. (Pubitemid 35205264)
28. Nolan D, Moore C, Castley A, et al. Tumor necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS. 2003;17:121-122.
29. Tarr PE, Taffé P, Bleiber G, et al. Modeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis. 2005;191:1419-1426. (Pubitemid 40563352)
30. Vonkeman HE, Napel CHH, Oeveren-Dybicz AM, et al. b3-Adrenergic receptor polymorphism and the antiretroviral therapy-related lipodys-trophy syndrome. AIDS. 2000;14:1463-1464. (Pubitemid 30459527)
31. Saumoy M, Veloso S, Alonso-Villaverde C, et al. PPARg Pro12Ala polymorphism in HIV-1-infected patients with HAART-related lipodys-trophy. Curr HIV Res. 2009;7:533-540.
32. Won JC, Park CY, Lee WY, et al. Association of plasma levels of resistin with subcutaneous fat mass and markers of inflammation but not with metabolic determinants or insulin resistance. J Korean Med Sci. 2009;4:695-700.
33. Makino H, Shimizu I, Murao S, et al. A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes. Endocr J. 2009;56:1049-1058.
34. Baba T, Endo T, Sata F, et al. The contributions of resistin and adiponectin gene single nucleotide polymorphisms to the genetic risk for polycystic ovary syndrome in a Japanese population. Gynecol Endocrinol. 2009;25:498-503.
35. Osawa H, Ochi M, Tabara Y, et al. Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf). 2008;1:74-80. (Pubitemid 351847266)
36. Ochi M, Osawa H, Hirota Y, et al. Frequency of the G/G genotype of resistin single nucleotide polymorphism at -420 appears to be increased in younger-onset type 2 diabetes. Diabetes. 2007;56:2834-2838. (Pubitemid 350044928)
37. Asano H, Izawa H, Nagata K, et al. Plasma resistin concentration determined by common variants in the resistin gene and associated with metabolic traits in an aged Japanese population. Diabetologia. 2010;53:234-246.
38. Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet. 2001;29:306-309. (Pubitemid 33096456)
39. Nagaev I, Bokarewa M, Tarkowski A, et al. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS One. 2006;1:e31.
40. Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 2007;92:2272-2279. (Pubitemid 46997133)
41. Kopp A, Buechler C, Neumeier M, et al. Innate immunity and adipocyte function: ligand-specific activation of multiple Toll-like receptors modulates cytokine, adipokine, and chemokine secretion in adipocytes. Obesity (Silver Spring). 2009;17:648-656.
42. Gharibeh MY, Al Tawallbeh GM, Abboud MM, et al. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab. 2010;36:443-449.